Presentations Efficacy and safety of the Bruton’s tyrosine kinase (BTK) degrader NX-5948 in patients with relapsed/refractory chronic lymphocytic leukemia: updated results from an ongoing Phase 1a/b study
Presentations NX-5948, a Clinical-Stage BTK Degrader, Achieves Deep Suppression of BCR, TLR, and FcR Signaling in Immune Cells and Demonstrates Efficacy in Preclinical Models of Arthritis and Other Inflammatory Diseases
Presentations IRAK4 Degrader GS-6791 Inhibits TLR and IL-1R-Driven Inflammatory Signaling, and Ameliorates Disease in a Preclinical Arthritis Model
Presentations An Orally Bioavailable, Brain Penetrant, Pan-Mutant BRAF Degrader for the Treatment of Primary and Inhibitor-Resistant Solid Tumors
Presentations Rational Discovery of a Small Molecule Intramolecular Glue Inhibitor of CBL-B that Enhances T-cell Function
Presentations Accelerating Targeted Protein Degrader Discovery with Automated and Integrated Direct-To-Biology Screening
'